Almac Diagnostic Services Limited

**The Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT)** is a partnership of Life and Health Science (LHS) companies and Academia, aligned to the strategies of both the Departments of Health and Economy of the NI devolved government to enhance health and wealth creation for NI citizens. Currently, NI has a significant presence in ...

One of the major issues when conducting clinical trials (CTs) in cancer is the need to pre-screen patients with one or more genomic tests to determine if the patient is likely to respond to the proposed new therapy. Typically this means that a tumour biopsy may be required to obtain DNA or RNA to carry out the required genomic testing. Many modern clinica...

This project will build a bioinformatics pipeline on top of the Analytics Engines big data platform enabling: diagnostic/companion diagnostic repositioning, target selection, data-driven drug discovery, data-driven drug repositioning and pre-clinicial model system alignment. This is enabled by driving the translation of bioinformatics pipelines from ad-ho...

The DDRD Breast Assay has been developed by Almac Diagnostics to help clinicians and patients decide on whether the use of chemotherapy may be an appropriate approach following surgery for early stage node negative breast cancer patients. Patients who are called “positive” are approximately 4 times less likely to have a relapse compared to patients who ar...

Awaiting Public Summary

Awaiting Public Summary